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According to the Centers for Disease Control and Prevention (CDC), the self-reported adult obesity (body mass index [BMI] ≥30 kg/m2) in the United 
States increased from 25.6% in 2007 to 26.7% in 2009.1 
Morbid obesity is also increasing at a fast rate. From 
2000–2005, the self-reported morbid obesity increased by 
50% for people with a BMI >40 kg/m2 and by 75% for 
those with a BMI >50 kg/m2.2 When diet, exercise, and 
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medication therapy fail to achieve adequate weight loss in 
morbidly obese individuals, bariatric surgery may be indi-
cated to induce weight loss and reduce obesity-related 
complications.3 In 2008, the American Society for 
Metabolic and Bariatric Surgery reported that an esti-
mated 220,000 morbidly obese individuals underwent 
bariatric surgery.4 Bariatric surgeries are classified in 3 
types of procedures: “restrictive,” which involves stomach 
size reduction and includes laparoscopic adjustable gas-
tric banding, vertical banded gastroplasty, and sleeve 
gastrectomy; “malabsorptive,” which bypasses large seg-
ments of the small intestines and includes the jejunoileal 
bypass that is no longer practiced because of its associ-
ated common and serious complications; and “restrictive-
malabsorptive,” which combines both types of procedures 
and includes the Roux-en-Y gastric bypass (RYGB) and 
the duodenal switch (DS) or the biliopancreatic diversion 
(BPD) with or without DS.5-8
The duodenal switch (DS) procedure is a type of restrictive-
malabsorptive bariatric surgery that is typically reserved for 
severe morbidly obese people (body mass index >50 kg/m2) 
with obesity-related comorbidities, when diet, lifestyle changes, 
and pharmacologic therapy fail to achieve adequate weight 
loss. Patients who undergo the DS procedure are at risk for 
malabsorption, malnutrition, and nutrient deficiencies. Copper 
deficiency is a commonly reported long-term complication of 
Roux-en-Y gastric bypass (RYGB) surgery. However, data are 
limited on copper deficiency–associated complications and 
their treatment in DS patients. This article presents a case of 
a patient who developed hypocupremia with associated pancy-
topenia, myeloneuropathy, and leukoencephalopathy following 
DS and reviews the literature related to the pathophysiology of 
copper deficiency and copper replacement in bariatric surgery 
patients. When severe diarrhea was present, intravenous 
elemental copper 4 mg (as cupric chloride)/d in addition to 
daily oral copper gluconate was necessary to correct the hypo-
cupremia and improve the hematologic indices and neurologic 
symptoms of copper deficiency. When diarrhea subsided, oral 
elemental copper 4 mg (as copper gluconate) 3 times daily 
maintained normal serum copper concentrations and avoided 
the relapse of severe neurologic dysfunction. Regular monitor-
ing of serum copper and ceruloplasmin concentrations is rec-
ommended following DS surgery to detect any copper 
deficiency before irreversible neurologic damage occurs. Long-
term copper supplementation is likely necessary to main-
tain normal copper status in DS patients. (Nutr Clin Pract. 
2011;26:583-592)
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The laparoscopic RYGB is the most commonly per-
formed bariatric surgery. It involves the construction of a 
small stomach pouch that is attached to a segment of the 
jejunum, thereby bypassing the duodenum and proximal 
jejunum.5 The DS procedure is much less commonly per-
formed and is reserved for severe morbidly obese indi-
viduals (BMI >50 kg/m2). It involves the resection of a 
large part (75%) of the stomach (restrictive), leaving a 
gastric sleeve of 100–200 mL, and the rearrangement of 
the small intestines (malabsorptive) in 2 limbs: (1) the 
alimentary limb (250 cm), which will carry the food and 
consists of the distal one-third of the small intestines that 
is attached to the small portion of the duodenum after it 
is transected 2–4 cm past the pylorus, and (2) the bilio-
pancreatic limb, which will carry the pancreatic and liver 
secretions into the distal ileum. Both limbs join at the 
bottom end of the small intestines to form a “common 
channel” (100 cm) where food and digestive secretions 
mix together before entering the colon (Figure 1).6-8 The 
bypass of the duodenum and jejunum significantly 
bypasses the absorption of proteins, carbohydrates, and 
most minerals and vitamins. Furthermore, less exposure 
to biliary secretions and pancreatic enzymes decreases the 
breakdown of proteins, carbohydrates, and fat. Because 
limited fat absorption occurs in the common channel, 
undigested fat enters the colon and causes diarrhea. The 
shorter the common channel, the more likely are the 
complications of diarrhea, malabsorption, protein-calorie 
malnutrition, and vitamin and mineral deficiencies. 
Revision or reversal of the DS may be considered in 
patients who develop intractable diarrhea and severe 
malnutrition, and who do not respond to dietary or phar-
macologic interventions.9,10
Patient Case
A 58-year-old man presented to our hospital on April 29, 
2010, with severe fatigue, confusion, progressive neu-
ropathies, ataxia, and gradual weight loss over the past 
year (30 kg weight loss beyond his maintenance body 
weight of 100 kg). The patient’s past medical history was 
significant for severe morbid obesity (baseline body weight = 
160 kg; BMI = 55 kg/m2) with comorbidities, including 
obstructive sleep apnea, type 2 diabetes mellitus, hyper-
tension (all of which have resolved), and gastroesopha-
geal reflux disease. His past surgical history was significant 
for the DS procedure, with appendectomy and cholecys-
tectomy in June 2001. According to the surgical report, 
the patient had about 120 mL of remaining stomach 
volume, an alimentary limb of 200 cm, and a common 
channel of 100 cm. The patient’s home medications 
included omeprazole, hydrochlorothiazide/losartan, and 
oral nutrient supplements of calcium, vitamin D, vitamin 
C, iron, and vitamin A. The patient had been consuming 
a regular diet until a week before this presentation when 
he began to have decreased appetite with reduced oral 
intake.
According to the medical history obtained from the 
patient and caregiver, the patient had bilateral numbness 
in his legs and thighs that first started about 2–3 years 
after his bariatric surgery in the lateral aspect of his left 
foot and toes and then slowly spread to the remainder of 
the left foot and then the right foot. These symptoms slowly 
progressed with time up to his thighs along with weakness 
and inability to lift his feet, difficulties of movement and 
ambulation, and lack of sensation. Over the past 6–12 
months, the patient had noticed difficulties in flexing his 
hands and inability to write with his right hand. He also 
had significant trouble maintaining his balance that 
recently necessitated the use of a cane, wheeled walker, 
wheelchair, or a power scooter. His caregiver described 
his voice as becoming weaker with lack of emotional abil-
ity. Since these symptoms began, the patient had under-
gone multiple clinical workups at outside hospitals and 
was diagnosed with neuropathy of unidentified etiology.
On physical exam, the patient was ill appearing with 
clinical signs of cachexia and malnutrition. He was hypo-
thermic (rectal temperature 30.7°C) and hypoglycemic 
(serum glucose concentrations 60 mg/dL; normal range, 
73–110 mg/dL). His hospital course progressed to wors-
ening weakness and altered mental status, with progres-
sive motor neuropathies, discoordination, confusion, 
 
Figure 1.  The duodenal switch procedure. Reprinted from 
Anthone GJ. The duodenal switch operation for morbid obesity. 
Surg Clin North Am. 2005;85(4):819-833. Copyright (2005), 
with permission from Elsevier.
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delirium, and lack of arousal to voice and noxious stimuli. 
The patient’s neurologic exam was suggestive of a mye-
loneuropathy with motor predominance, leukoencepha-
lopathy, and optic neuropathy.
Outside reports of electromyogram (EMG) and nerve 
conduction studies from December 2009 showed evi-
dence of severe axonal polyneuropathy (motor greater 
than sensory) that involved the lower more than the 
upper extremities. The active denervation and neurogenic 
motor units that were seen in the distal extremities sug-
gested a chronic, length-dependent process but without 
evidence of myopathy, widespread denervation to suggest 
motor neuron disease, or lumbosacral radiculopathy.
During the patient’s hospital stay, additional workups 
included a head computed tomography (CT) without con-
trast that showed no definite acute intracranial abnormal-
ity. A head magnetic resonance imaging (MRI) showed 
diffuse white matter disease, primarily in the subcortical 
white matter following pyramidal tracts without evidence 
for stroke. Electroencephalography (EEG) was consistent 
with mild to moderate diffuse encephalopathy with no 
seizures or epileptiform discharges. Abdominal ultra-
sound showed diffuse fatty infiltration of the liver. Chest 
CT showed no evidence of malignancy within the thorax 
or pneumonia.
Further clinical workups showed normal tests for 
all of the following: anti-double-stranded DNA immuno-
fixation; serum protein electrophoresis; antinuclear anti-
body; anti-Sm, anti-double-stranded DNA, anti-RNP, 
anti-Ro, anti-La, antiendomysial, and anti-glutaminase 
antibodies; erythrocyte sedimentation rate; creatine 
kinase; aldolase; oral glucose tolerance; urine protein 
electrophoresis; serum-free light chains; thyroid stimula-
tion hormone; lactate dehydrogenase; ammonia; 
C-reactive protein; homocysteine; fasting lipid panel; 
urine analysis; rapid plasma reagin; varicella zoster virus; 
cytomegalovirus; and human immunodeficiency virus. 
Hepatitis B surface antibody and hepatitis C antibody 
were nonreactive. Cerebrospinal fluid cultures were all 
negative. Serum alanine aminotransferase and aspartate 
aminotransferase were elevated denoting transaminitis. 
Prothrombin time, the international normalized ratio, 
and partial thromboplastin time were all elevated.
Further blood workup showed copper and zinc defi-
ciencies, hypoalbuminemia, anemia, neutropenia, throm-
bocytopenia, and low iron levels (Tables 1 and 2). Serum 
copper concentrations were 0.2 mcg/mL (normal range, 
0.7–1.4 mcg/mL) and ceruloplasmin at 5 mg/dL (normal 
range, 16–36 mg/dL). At baseline, serum concentrations 
of vitamin A (retinol; 151 mcg/L [normal range, 325–780 
mcg/L]), vitamin E (α tocopherol; 4.3 mg/L [normal 
range, 5.5–17 mg/L]), and 25-hydroxyvitamin D (8 ng/mL 
[normal range, 25–80 ng/mL]) were all decreased. 
Baseline blood concentrations of red blood cell vitamin 
B1 (100 nmol/L [normal range, 80–150 nmol/L]), vitamin 
B6 [11 mcg/L [normal range, 5–50 mcg/L]), folic acid (11 
ng/mL [deficient <0.3 ng/mL]), vitamin B12 (603 pg/mL 
[normal range, 211–911 pg/mL]), and methylmalonic 
acid (0.11 µmol/L [normal ≤0.4 µmol/L]) were all normal.
The patient was diagnosed with severe copper defi-
ciency complicated by pancytopenia and neurologic dys-
function. A copper replacement regimen was initiated 
with intravenous elemental copper 2.4 mg (as cupric 
chloride)/d (total dose mixed in 100 mL of 0.9% sodium 
chloride and infused over 2 hours) for 7 days and there-
after converted to oral elemental copper 4 mg (as copper 
gluconate) twice daily along with intravenous elemental 
copper 2.4 mg (as cupric chloride) once weekly. After 9 
days of hospital stay, serum copper concentrations 
increased to 0.6 mcg/mL. Although the patient’s clinical 
status stabilized, he continued with weakness and poor 
proprioception in his distal upper extremities and bilateral 
Table 1.  Laboratory Parameters
     Blood Levels With Corresponding Collection Dates
Laboratory Tests (Normal 
Range) 4/30/2010 5/28/2010 7/7/2010 10/1/2010 1/12/2011 2/4/2011 4/1/2011
Copper (0.7–1.4 mcg/mL) 0.2 0.7 0.5 0.6 0.8 0.9 0.7
Ceruloplasmin (16–36 mg/dL) 5 14.7 10.9 13.6 16.9 17.5 13.2
Zinc (0.5–1.5 mcg/mL) 0.4 0.6 0.6 0.6 0.6
Albumin (3.5–4.9 g/dL) 2.8 2.9 2.7 1.8 3.8 4.3 4.2
WBC (4–10 k/mm3) 2.4 3.1 3.4 2.4 3.3 4.7 4.9
Hemoglobin (13.5–17 g/dL) 10.4 9.6 10.3 9.6 10 10.8 11.5
Hematocrit (40–50%) 32.7 31.5 32.8 30.4 33.3 34.3 37.7
Platelet count (150–400 k/mm3) 118 201 219 45 236 214 226
RBC (4.4–5.7 m/mm3) 3.44 3.49 3.85 3.23 4.2 4.4 4.88
MCV (79–99 fl) 94.9 90.1 85.3 94.2 79.3 78.1 77.3
MCV, mean corpuscular volume; RBC, red blood cell count; WBC, white blood cell count.
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weakness in his lower extremities, and his mental status 
continued to fluctuate. He was discharged to a subacute 
rehabilitation facility with a plan to follow up as an out-
patient with the neurology clinic. His copper supplemen-
tation regimen upon discharge consisted of oral elemental 
copper 4 mg (as copper gluconate) twice daily with intra-
venous elemental copper 2.4 mg (as cupric chloride) once 
weekly. Home oral copper supplementation was later 
increased to elemental copper 4 mg (as copper gluconate) 
3 times daily.
On October 1, 2010, the patient was readmitted to 
the inpatient general medicine service for mental status 
changes, progressive generalized weakness, functional 
impairment, anasarca, and severe diarrhea (up to 8 loose 
stools per day). With regard to his diarrhea, tests for 
celiac disease and Clostridium difficile infection were 
negative. Stools were also negative for fecal leukocytes or 
white blood cells. The patient was therefore started on 
parenteral nutrition (PN) on October 5, 2010, due to 
malabsorption and malnutrition. His PN was initially sup-
plemented with elemental copper 2 mg (as cupric 
chloride)/d. The parenteral copper dose was thereafter 
increased to 3 mg and then 4 mg/d in PN because of per-
sistently low serum copper concentrations. Oral copper 
supplementation was continued with elemental copper 4 
mg (as copper gluconate) 3 times daily. Considering the 
patient’s impaired activities, functional deficits, and gait 
dysfunction, he was transferred to the inpatient physical 
therapy and rehabilitation service. With rehabilitation 
and treatment, the patient’s cognition noticeably 
improved. He regained more control of his fingers and 
was able to ambulate with a walker. After 3 weeks of reha-
bilitation, the patient was discharged from the hospital on 
daily home PN that provided elemental copper 4 mg (as 
cupric chloride)/d. Oral elemental copper 4 mg (as gluco-
nate) 3 times daily was also continued.
On November 9, 2010, the patient was seen in the 
surgery clinic in follow-up to his continued diarrhea. He 
was started on pancreatic enzyme supplementation 
(Creon, pancrelipase delayed-release oral capsules; Abbott 
Laboratories, Abbott Park, IL) that consisted of 2 cap-
sules (each capsule provides lipase 24,000 USP units, 
protease 76,000 USP units, and amylase 120,000 USP 
units) orally 3 times daily with meals. The plan was to 
consider revising the DS if diarrhea and malabsorption 
did not resolve with pancreatic enzyme therapy. Following 
several days of pancreatic enzyme supplementation, the 
patient reported that his diarrhea decreased to 2–3 stools 
daily and was therefore continued on the same pancreatic 
enzyme therapy.
On December 12, 2010, the patient was readmitted 
to the hospital for fluid overload with 1+ bilateral lower 
extremity edema to the knees and orthopnea. He was 
diagnosed with pulmonary edema and diastolic heart fail-
ure. Given his decreased diarrhea and improved dietary 
intake and nutrition status, PN was discontinued, and the 
patient was discharged home on his previous oral copper 
gluconate maintenance regimen.
On January 25, 2011, the patient was seen in follow-
up in the neuromuscular disorders clinic. He had 
increased energy and appetite. His neurological exam 
showed significant improvement, with normal mental 
status, strength coordination, and reflexes. He was able to 
do most activities of daily living, although he still had 
some difficulties with balance and was using a walker or 
scooter for ambulation. His hematological parameters 
and serum copper concentrations were maintained within 
the normal range. Figure 2 depicts the daily copper intake 
and corresponding serum copper concentrations during 
the patient’s follow-up period.
Discussion
Copper Homeostasis
Copper is a trace metal that is involved in several enzy-
matic and metabolic functions (Table 3).11 The dietary 
reference intake (DRI) for copper in adults (nonpregnant, 
nonlactating) is 0.9 mg/d, with the typical U.S. diet pro-
viding copper 2–5 mg/d.12,13 Copper-rich foods include 
whole grains, nuts, cereals, beans, organ meats (espe-
cially liver), shellfish, oysters, and dark green leafy vege-
tables. About 30%–40% of copper is absorbed throughout 
the small intestines, with a smaller proportion absorbed in 
the stomach. The acidic milieu of the stomach is favorable 
Table 2.  Iron Studies
                  Blood Levels With Corresponding Collection Dates
Laboratory Tests (Normal Range) 5/5/2010 7/7/2010 10/11/2010 1/24/2011
Iron (33–150 mcg/dL) 14 50 42 46
IBC (220–440 mcg/dL) 242 264 277 407
TSAT (20%–50%) 5.8 18.9 15.2 11.3
Ferritin (18–320 ng/mL) 402.8 436 271.4 93
IBC, iron binding capacity; TSAT, percent transferrin saturation.
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for releasing copper from food complexes, which facili-
tates its absorption in the proximal duodenum. However, 
as intestinal pH increases, a smaller proportion of copper 
is solubilized and absorbed. Therefore, copper absorption 
is at its highest in the upper small bowel and at its lowest 
in the ileum.14
Copper crossing of the intestinal apical membranes is 
mainly facilitated by the copper transporter Ctr1 located 
on the luminal surface, although passive copper diffusion 
may also occur especially with high copper intake.15-18 
The presence of metalloreductases and other transporters 
in the brush-border membrane may also play a role in 
copper absorption.13,18-20 Copper absorption occurs pri-
marily via rate-limiting active transport mechanisms.15 
Although the absolute amount of copper absorbed 
increases directly with the dose, the relative bioavailabil-
ity of copper decreases with increasing dose.21,22 With 
dietary copper intake at 7.5 mg/d, only 12% is absorbed, 
whereas copper 0.8 mg/d and 1.7 mg/d resulted in 56% 
and 36% of copper absorbed, respectively.22 Copper is 
then stored inside the enterocyte by combining with the 
intracellular cytoplasmic protein metallothionein until it 
interacts with the copper-transporting ATPase enzyme for 
transfer into the systemic circulation.23
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Figure 2.  Daily copper doses and serum copper concentrations.
Table 3.  Examples of Physiologic Functions of Copper-Dependent Enzymes11, 25
Copper-Dependent Enzymes Physiologic Functions
Amine oxidases Primary amines deamination
Catechol oxidase Melanin synthesis
Cytochrome-c oxidase Adenosine triphosphate synthesis, electron transport
Dopamine-β monooxygenase Dopamine to norepinephrine conversion
Ferroxidases I and II (ceruloplasmin) Ferrous iron oxidation and mobilization
Lysyl oxidase Elastin and collagen cross-linking, formation of connective tissue
Peptidylglycine monooxygenase Bioactive peptides synthesis, α-amidation of neuropeptides
Phenylalanine hydroxylase Phenylalanine oxidation to tyrosine
Superoxide dismutase Free radical scavenging
Tyrosinase Melanin synthesis from tyrosine
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Once in the bloodstream, copper binds to albumin 
and is transported to the portal blood, where it undergoes 
enterohepatic recycling. Total body copper is estimated at 
100 mg in adults, with the liver storing the majority of body 
copper. A downregulation effect of copper release by the 
liver has been postulated, which may play a role in prevent-
ing copper loading when excessive copper intake occurs.16 
In the liver, small copper fractions are used for the synthesis 
of ceruloplasmin and other copper proteins. Ceruloplasmin 
is the major copper transporter that binds and transports 7 
copper atoms per molecule in the blood. It has a biological 
half-life of about 7 days, whereas the more labile copper-
bound albumin has a much shorter half-life of 10 minutes. 
Copper is primarily eliminated via the bile, with more than 
95% of oral copper found in the feces, leaving only about 
1%–5% of copper to be excreted in the urine. However, 
biliary copper is strongly bound to bile, which makes it 
poorly bioavailable.13 There appears to be a direct relation-
ship between copper intake and copper excretion, which 
further helps regulate body copper homeostasis.22
Bariatric Surgery and Copper Deficiency
Copper deficiency has been typically reported in malab-
sorption syndromes (eg, small bowel resections, chronic 
diarrhea, short bowel syndrome) as a result of decreased 
intestinal absorption.11 With the increased number of bar-
iatric surgeries performed, cases of copper deficiency have 
been more frequently reported in patients who underwent 
different bariatric surgery procedures, mainly with RYGB,24-34 
with limited information available on copper deficiency 
and treatment following DS. In a 3-year follow-up study of 
64 morbidly obese individuals who underwent BPD, 
asymptomatic but significant decreases from baseline in 
serum copper concentrations were detected at 6 months 
and up to 3 years after BPD despite oral elemental copper 
supplementation of 4 mg/d. The percentage of patients 
with low serum copper concentrations significantly 
increased from 23% at 6 months to 70% at 3 years after 
BPD as compared to baseline (P < .05).35 In another 5-year 
follow study that compared serum copper and zinc concen-
trations in patients who underwent RYGB (n = 52) or BPD 
(n = 89), hypocupremia and hypozincemia occurred more 
frequently in BPD as compared to RYGB patients. Average 
serum copper concentrations progressively decreased in 
BPD patients, reaching their lowest levels 24 months fol-
lowing BPD surgery. However, no hematologic or neuro-
logic complications were reported with hypocupremia.36
Predisposing factors to copper deficiency following 
bariatric surgery are mainly related to decreased copper 
intake and absorption and increased losses. Reduced 
dietary copper intake due to reduced gastric volume, 
changes in gastrointestinal pH, bypass of small bowel seg-
ments, and diarrhea, along with cell mass breakdown 
following significant weight loss, are contributing factors 
to copper deficiency in bariatric surgery patients. 
Furthermore, acid secretion is almost absent in the 
remaining stomach sleeve,37 therefore decreasing free 
copper availability for absorption. Another major limiting 
factor to copper absorption in DS patients is the bypass 
of the duodenum and jejunum, the main sites for copper 
absorption. This leaves the alimentary limb with the com-
mon channel as the remaining sites where copper can be 
absorbed. However, little free copper is typically absorbed 
in the ileum because of the high intraluminal pH and the 
formation of mostly insoluble cupric hydroxide and basic 
cupric salts.14 In 1 clinical study, there was no correlation 
between the length of the common channel and serum 
copper concentrations in BDP patients.36 Furthermore, it 
is unknown if ileal adaptation to increasing copper 
absorption occurs in humans following intestinal bypass 
surgery, similar to the intestinal adaptation that occurs 
following small bowel resections. In an animal study that 
involved a 50% resection of the proximal (starting 3 cm 
distal to the ligament of Treitz) and distal (down to 15 cm 
from the ileocecal valve) small bowel, there was a signifi-
cant ileal adaptation with increased mucosal growth and 
copper concentrations in the ileal mucosa but not in the 
duodenum or midgut.38 In animal models of RYGB, intra-
luminal nutrients stimulated intestinal adaptation 
(increased intestinal width, villus height, crypt depth, 
and proliferation) in the alimentary limb, whereas gluca-
gon-like peptide-2 (GLP-2) stimulated to a lesser extent 
biliary limb adaptation.39 Therefore, a possible combina-
tion of ileal adaptation, upregulation of copper absorp-
tion,40 and mobilization of liver copper reserves16 are 
plausible mechanisms to understand the delayed appear-
ance of copper deficiency in patients who undergo bariat-
ric surgery. It can be then postulated that the adaptation 
of the alimentary limb and the common channel may 
possibly allow sufficient copper absorption to maintain 
normal serum copper concentrations in patients with 
DS. However, this postulated mechanism requires 
evaluation.
Biochemical Signs and Clinical Manifestations 
of Copper Deficiency
Biochemical signs of copper deficiency are reflected in 
serum copper and ceruloplasmin concentrations below 
the normal range. Severe copper deficiency may present 
as pancytopenia (neutropenia, thrombocytopenia, iron-
resistant hypochromic normocytic or macrocytic anemia) 
and/or neurologic dysfunction that may include periph-
eral neuropathy, myelopathy, spastic gait, ataxia, optic 
neuropathy, encephalopathy, central nervous system 
demyelination, polyradiculoneuropathy, and rhomben-
cephalopathy.41-48 Hypotonia and increased infection risk 
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have also been reported, as well as bone abnormalities 
such as osteoporosis, separation of epiphyses, and frac-
tures of ribs and long bones, especially in children.11
Typically, the neurologic manifestations related to 
severe copper deficiency appear after years of longstanding 
copper depletion in patients who underwent bariatric sur-
gery.36,48 The earliest neurologic changes are typically 
related to vitamin B1 deficiency, whereas the delayed com-
plications that affect the spinal cord and peripheral nerves 
are mostly related to copper and/or vitamin B12 deficien-
cies.45,48,49 In a study of 20 adult patients who underwent 
partial gastrectomy, a mean of 20.7 years elapsed before 
the detection of copper deficiency, although no correlation 
was found from the time of gastric resection to the 
decreased serum copper and ceruloplasmin concentra-
tions.44 To the contrary, early-onset copper deficiency at 14 
months following RYGB bypass surgery has been reported,34 
which makes the prediction of the onset of hypocupremia 
difficult across the diverse patient populations who undergo 
bariatric surgery. Slow and subclinical copper deficiency 
likely occurs before clinical symptoms of severe copper 
deficiency become apparent. Interindividual variation is 
likely when considering differences in baseline nutrition 
status, copper intake, and the type of bariatric surgery per-
formed.
Copper Supplementation and  
Patient Outcomes
The goals of copper supplementation in a copper-defi-
cient patient are to treat the associated clinical signs and 
symptoms, normalize serum copper concentrations, 
restore body copper stores, and prevent future deficiency 
or relapse. However, the optimal copper dosing to treat 
the neurologic manifestations in acquired copper defi-
ciency secondary to bariatric surgery is largely empirical. 
Furthermore, the correlation between serum copper con-
centrations, tissue copper stores, and neurologic recovery 
is unknown. Therefore, copper dosing should be individu-
alized based on clinical response and changes in serum 
copper and ceruloplasmin concentrations.
Oral and/or enteral elemental copper intake of 2–10 
mg with or without intravenous copper supplementation 
has been used to correct copper deficiencies in gastric 
bypass patients.24,25,28,30,34,50,51 In our report, oral elemental 
copper 4 mg (as copper gluconate) 3 times daily success-
fully maintained normal serum copper and ceruloplasmin 
concentrations and prevented relapse. Copper gluconate is 
a commonly used oral copper supplement, but its optimal 
dosing and duration to correct copper deficiency are 
unknown. Because copper gluconate is highly soluble, it 
is prone to binding by complexing agents (eg, dietary fib-
ers, fructose) in the intestinal tract.15,52 This may require 
higher copper gluconate doses and extended duration of 
therapy for adequate copper repletion. In a small study of 
7 healthy adult volunteers, copper gluconate supplemen-
tation at 10 mg/d for 12 weeks resulted in no significant 
increase in serum copper concentrations as compared to 
baseline.52 However, the study is limited by its small sam-
ple size and its enrollment of healthy volunteers, who may 
have different absorptive patterns as compared to gastric 
bypass patients. Another oral copper salt form, copper 
acetate, has also been used to correct copper defi-
ciency.43,53 In a patient who developed myelopathy sec-
ondary to copper deficiency following vertical banded 
gastroplasty, elemental copper 4 mg (as copper acetate)/d 
with additional elemental copper 2 mg/d from an oral 
multivitamin/multitrace element supplement improved 
the neurological symptoms and corrected the hemato-
logical parameters of copper deficiency.53
In patients with malabsorption, intravenous cupric 
chloride has been used for copper repletion. The initial 
intravenous copper dosing regimen used in our patient 
was based on previous reports of copper supplementation 
in 2 patients with severely low serum copper and cerulo-
plasmin concentrations following bariatric surgery.24 One 
53-year-old patient presented 21 years after RYGB with 
abnormal gait, painful paresthesias in lower extremities, 
neutropenia, and anemia. The other 58-year-old patient 
presented 10 years after an unspecified bariatric surgery 
with anemia, neutropenia, ataxia, numbness, paresthesias 
in lower extremities and hands, and wheelchair depend-
ence. Initially, intravenous copper 2.4 mg/d was given for 
6 days to both patients and then changed to once-weekly 
infusion along with oral elemental copper 8 mg (as cop-
per gluconate)/d for 21 weeks, followed by 7 weeks of 
only oral copper supplementation. In the first patient, 
hematologic parameters and serum copper concentra-
tions normalized and the paresthesias improved after 1 
month of copper supplementation. However, there was 
no improvement in lower extremity vibratory sensations 
and proprioception. In the second patient, hematologic 
parameters normalized within 1 week of copper supple-
mentation, and the light touch sensation gradually 
improved over several weeks. However, it was not until 7 
months after copper repletion that the patient could walk 
without assistance.24 In our patient case, weekly doses of 
intravenous copper 2.4 mg in addition to oral elemental 
copper 8 mg (as copper gluconate)/d marginally corrected 
serum copper concentrations and were not associated 
with significant clinical improvement. However, intrave-
nous elemental copper 4 mg (as cupric chloride)/d in PN 
in addition to oral elemental copper 12 mg (as copper 
gluconate)/d divided into 3 doses maintained normal 
serum copper and ceruloplasmin concentrations and sig-
nificantly improved the hematologic parameters and neu-
rologic symptoms.
In summary, hematologic abnormalities appear to 
recover first in response to copper supplementation,44 
although clinical relapse may occur with inadequate copper 
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intake.53 This is similar to our patient case when blood 
indices were first to respond to improved copper status, 
but neurologic symptoms relapsed after initial improve-
ment. Higher copper doses were required until significant 
neurologic improvement and stabilization were observed. 
However, despite normalization of serum copper and 
ceruloplasmin concentrations, neurologic manifestations 
may only partially improve or stabilize rather than fully 
recover.24,48-51,54
Coexisting Micronutrient Deficiencies
Severe copper and/or vitamin B12 deficiencies have similar 
neurologic manifestations and may coexist in bariatric sur-
gery patients.33,45,46,50,53,55 Both copper and vitamin B12 
deficiencies should be ruled out and corrected as neces-
sary. In DS patients, vitamin B1 deficiency resulting in 
peripheral neuropathy49 and vitamin A deficiency resulting 
in night blindness have been reported.56 Other water-solu-
ble (vitamin C, folate) and fat-soluble (vitamins D, E, and 
K) vitamin deficiencies may also occur and should be ruled 
out.9,24,45,48,49,57,58 Furthermore, copper and zinc deficien-
cies may coexist and are prevalent following DS.35,36,53 
However, high zinc intake has shown to decrease copper 
absorption and result in copper defciciency.41,43,50,59,60 A 
possible mechanism by which zinc inhibits copper absorp-
tion is by inducing the intestinal metallothionein that 
sequesters copper inside the intestinal cells, and copper 
will get eliminated in the stools when enterocytes are des-
quamated.61 Because endogenous zinc primarily undergoes 
fecal elimination via small intestinal mucosa and pancre-
atic secretions,62,63 intravenous zinc supplementation could 
theoretically inhibit copper absorption by indirectly allow-
ing more intestinal zinc delivery, although it is unknown 
how these interactions may play out in DS patients. 
Regardless, in cases of simultaneous copper and zinc defi-
ciencies, the intravenous route should preferably be used 
for the supplementation of both trace metals. Intravenous 
copper is available in the forms of cupric chloride (0.4 mg 
elemental copper/mL in 1.07 mg cupric chloride salt) and 
cupric sulfate (0.4 mg elemental copper/mL in 1.57 mg 
cupric sulfate salt).64 Intravenous zinc is available as zinc 
chloride (1 mg elemental zinc/mL in 2.09 mg zinc chloride 
salt) and zinc sulfate (1 mg elemental/mL zinc in 4.39 mg 
zinc sulfate salt).65 If the oral route is used, oral copper and 
zinc supplements should be administered at distant times 
as possible, although the optimal separation time to avoid 
competitive inhibition of absorption is unknown, and the 
interaction between copper and zinc may not be com-
pletely avoided.66
Other metal (calcium, magnesium, iron, selenium) 
deficiencies may also coexist and should be ruled out and 
corrected as necessary, especially with diarrhea and mal-
absorption.67-69 Copper is essential for transferrin forma-
tion, and because copper deficiency inhibits liver iron 
mobilization, hypocupremia may result in microcytic 
hypochromic anemia.70 Furthermore, the divalent metals 
copper, iron, and zinc compete for absorption in the duo-
denum and proximal jejunum, and excess intake of one of 
these metals may inhibit the absorption of the others. It 
remains unknown, however, if this competition for absorp-
tion occurs in the alimentary limb and common channel 
of DS patients.
Conclusion
DS is associated with severe malabsorption, malnutrition, 
and nutrient deficiencies. Copper deficiency is a compli-
cation of DS, and its clinical manifestations may not 
appear until months to years after surgery. Intravenous 
copper supplementation should be used for copper reple-
tion when diarrhea is present. When diarrhea is absent, 
oral elemental copper 4 mg (as copper gluconate) 3 times 
daily maintains normal serum copper concentrations. 
Early and periodic monitoring of copper status is neces-
sary following DS surgery to detect and treat any copper 
deficiency before severe or irreversible neurologic damage 
occurs. Chronic copper supplementation is likely neces-
sary to maintain normal copper status in DS patients.
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